Education
About Us
Working with TipRanks
Follow Us
Genetic Technologies (AU:GTG)
ASX:GTG
GTG Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.18
Previous CloseN/A
Volume10.07K
Average Volume (3M)0.00
Market Cap
$9.45M
Enterprise ValueAU$9.77M
Total Cash (Recent Filing)AU$3.23M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding242,362,080
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.63
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Genetic Technologies News
PremiumCompany Announcements
Genetic Technologies Creditors Approve Benelong DOCA Proposal
PremiumCompany Announcements
Genetic Technologies Considers DOCA Amid Voluntary Administration
PremiumCompany Announcements
Genetic Technologies Faces Potential Wind-Up Amidst Insolvency
PremiumCompany Announcements
Genetic Technologies to Divest DTC Businesses in Strategic SalePremiumCompany Announcements
Genetic Technologies Sells geneType Business to Rhythm Biosciences
PremiumCompany Announcements
Rhythm Biosciences Expands with Genetype Acquisition---
GTG FAQ
What was Genetic Technologies’s price range in the past 12 months?
Genetic Technologies lowest share price was AU$0.04 and its highest was AU$0.18 in the past 12 months.
What is Genetic Technologies’s market cap?
Genetic Technologies’s market cap is $9.45M.
When is Genetic Technologies’s upcoming earnings report date?
Genetic Technologies’s upcoming earnings report date is Aug 28, 2025 which is in 168 days.
How were Genetic Technologies’s earnings last quarter?
Currently, no data Available
Is Genetic Technologies overvalued?
According to Wall Street analysts Genetic Technologies’s price is currently Overvalued.
Does Genetic Technologies pay dividends?
Genetic Technologies does not currently pay dividends.
What is Genetic Technologies’s EPS estimate?
Genetic Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Technologies have?
Genetic Technologies has 242,362,080 shares outstanding.
What happened to Genetic Technologies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Genetic Technologies?
Currently, no hedge funds are holding shares in AU:GTG
---
Genetic Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:GTG Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-181.97%
Trailing 12-Months
Asset Growth
-58.22%
Trailing 12-Months
Company Description
Genetic Technologies
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
---
Technical Analysis
CardieX Limited
―
Resonance Health Ltd
―
Race Oncology Ltd.
―
Australian Clinical Labs Ltd
―
Botanix Pharmaceuticals Limited
―
---